Branched Chain Amino Acids Ratio in Medical Foods

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03539809

Recruitment Status : Unknown

Verified May 2018 by Rajavel Elango, PhD, University of British Columbia.
Recruitment status was: Recruiting

First Posted : May 29, 2018

Last Update Posted : May 29, 2018

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Rajavel Elango, PhD, University of British Columbia

Study Description

Brief Summary:

This study will evaluate the branched-chain amino acids (BCAA) ratio in the medical foods formulated for Methylmalonic and Propionic Acidemias (MMA/PROP) patients. We will recruit 6 healthy children between 6-10y (3 boys and 3 girls). They will be given amino acid-based shakes and protein free cookies. Using a minimally invasive stable isotope based technique, we will be able to determine the optimal ratio of BCAA to be added in the medical foods for the MMA/PROP subjects.

Condition or disease	Intervention/treatment	Phase
Children	Dietary Supplement: L-Amino Acids	Not Applicable

Show detailed description

Detailed Description:

Purpose:

The purpose of this study is to use the minimally invasive Indicator Amino Acid Oxidation (IAAO) method in healthy school-aged children to determine the optimal ratio of BCAA in current medical foods used by MMA/PROP subjects. We will recruit healthy children to test our hypothesis.

Hypothesis:

The IAAO will be high (suggesting low protein synthesis) at high leucine levels and will be low (suggesting optimal protein synthesis) when leucine levels are reduced and at a better-balanced ratio of leucine to isoleucine and valine.
Children will have low levels of urine excretion of isoleucine and valine, with high leucine urinary excretion, when given the high ratio of leucine to valine and isoleucine. With the reduction of leucine intake in the diet, the urinary concentration of both isoleucine and valine will normalize.

Justification:

The use of medical foods as a sole source of energy and protein in patients with MMA/PROP has been discouraged. The recommendations state that such medical foods should be only used for patients who can't consume their RDA from natural protein. Since most of these patients are poor eaters, and at risk for malnutrition, they depend on medical foods as an easy tolerable source of energy and protein. The medical foods formulated for MMA/PROP contain imbalanced BCAA ratio (high leucine to minimal or no valine and isoleucine). The high leucine levels antagonize the other two BCAA and even suppresses their plasma and urine levels below normal. Determining the optimal ratio of BCAA is necessary to optimize protein synthesis, growth and prevent the accumulation of toxic metabolites. This proposal will focus on applying stable isotope tracers in healthy children to examine different intakes of leucine while keeping the amount of valine and isoleucine restricted as per the recommendations. Using the minimally invasive indicator amino acid technique (IAAO), and L-1-13C-Phenylalanine as the indicator amino acid for protein synthesis, the optimal amount of leucine to be added in one of the most commonly used medical food for these patients will be tested. In addition, the leucine intake which normalizes urine isoleucine and valine excretion will also be determined to be useful for patient management. Starting with the studies on healthy children ages 6-10 years to allow for characterization of the metabolic response to the different leucine intakes. Consequently, based on the results we obtain, we will be able to design the studies in MMA/PROP patients with the appropriate BCAA ratios to test.

Objectives:

Our primary objective is to examine the impact of reducing leucine levels from the current high doses in medical foods, sequentially, while holding isoleucine and valine at MMA/PROP recommended intakes, on protein synthesis using the IAAO technique in healthy children (6-10y).
Our secondary objective is to determine the impact of reducing leucine levels from the current high doses in medical foods, sequentially, while holding isoleucine and valine at MMA/PROP recommended intakes, on urinary excretion of BCAA.

Research Design:

This is a repeated measure study design involving 1 pre-study visit and 6 studies visits for each child, approximately one week apart from each other.

Statistical Analysis:

Results will be expressed as means ± SDs. Repeated Measures ANOVA will be used to assess the relationship of phenylalanine oxidation, and BCAA urinary excretion to the variable BCAA intakes using SAS statistical software (version 9.4; SAS Institute, Cary, NC). In all cases, the difference will be considered significant at P < 0.05. Repeated measure ANOVA will be used to measure the difference between means of F13CO2 oxidations in response to 6 leucine test intakes, as well as means of BCAA urinary excretions. When warranted, post hoc analysis will be performed using Tukey's multiple comparisons test to confirm where the differences occur between different conditions (leucine test intakes).

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	6 participants
Allocation:	N/A
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Basic Science
Official Title:	Determining the Optimal Ratio of Branched Chain Amino Acids in Medical Foods for Methylmalonic and Propionic Acidemias (MMA/PROP)
Estimated Study Start Date :	June 1, 2018
Estimated Primary Completion Date :	May 31, 2019
Estimated Study Completion Date :	May 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Propionic acidemia

Drug Information available for: Amino acids

Genetic and Rare Diseases Information Center resources: Propionic Acidemia

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: BCAA Ratio Different Branched-chain amino acid (BCAA) ratios will be tested. BCAA are comprised of 3 different amino acids (leucine, isoleucine and valine). The ratios among these 3 amino acids will be tested at 6 different ratios. Each intervention will be for 8hours.	Dietary Supplement: L-Amino Acids 6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.

Outcome Measures

Primary Outcome Measures :

13C Phenylalanine Oxidation [ Time Frame: 8 hours ]
Breath and Urine samples will be collected during the study to measure 13C Phenylalanine oxidation

Secondary Outcome Measures :

Urinary Branched Chain amino acids excretion [ Time Frame: 8 hours ]
Urine samples will be collected during the study to measure BCAA urinary excretion

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	6 Years to 10 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy school-aged children 6-10y
Normal weight
Normal eating habits
English speaking children

Exclusion Criteria:

Children under 6 years old, or over 10 years old.
Children who are currently ill, with a fever, cold, vomiting or diarrhea.
Children outside of normal weight parameters (3rd -85th percentiles for weight).
Children with claustrophobia.
Children currently or recently taking medication or antibiotics.
Children with food allergies.
Children who cannot speak, write and read in English

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03539809

Contacts

Layout table for location contacts

Contact: Rajavel Elango, Ph.D	604 875 2000 ext 4911	relango@bcchr.ubc.ca
Contact: Haneen Saleemani, MSc	604 875 2000 ext 4607	haneen.saleemani@bcchr.ubc.ca

Locations

Layout table for location information

Canada, British Columbia
BC Children's Hospital Research Institute, University of British Columbia	Recruiting
Vancouver, British Columbia, Canada, V5Z4H4
Contact: Rajavel Elango, Ph.D

Sponsors and Collaborators

University of British Columbia

Investigators

Layout table for investigator information

Principal Investigator:	Rajavel Elango, Ph.D	University of British Columbia

More Information

Layout table for additonal information

Responsible Party:	Rajavel Elango, PhD, Principal Investigator, University of British Columbia
ClinicalTrials.gov Identifier:	NCT03539809
Other Study ID Numbers:	H18-00439
First Posted:	May 29, 2018 Key Record Dates
Last Update Posted:	May 29, 2018
Last Verified:	May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Rajavel Elango, PhD, University of British Columbia:


Branched Chain Amino Acids Direct Amino Acid Oxidation Stable isotopes

To Top